WinSanTor is developing a proprietary first-in-class therapy to prevent and reverse nerve damage. Our lead compound, WST01, is a well-characterized off-patent compound with an established safety history that has been used for many years against an unrelated indication, this may allow a direct path to market and reducing development time and cost.
WST01 prevents, mitochondrial dysfunction, nerve fiber depletion and sensory loss in several distinct animal models of peripheral neuropathy.
We are strategically expanding WST01’s indications to all neuropathies, such as chemo induced and HIV related. Additionally, WST01 is just one compound we are investigating in a family of promising compounds that we have exclusive world wide rights to.
Conquering Diabetic Neuropathy
Drs. Calcutt and Fernyhough on WST01 and on treating and preventing nerve damage caused by diabetes.